



## PROGRAMME OVERVIEW

update May 19, 2022

May 24, 2022

Venue: CORPUS CONGRESS CENTRE - Oegstgeest  
the Netherlands

## *‘Breaking barriers for our future’*

07:45      **Registration desks open breakfast sessions**

---

08:00      **CxO breakfast meeting:** for CEOs, CFOs, COOs and CBOs active in the life sciences sector  
Besides a nice and healthy breakfast new companies that started their business recently at the Leiden Bio Science Park will introduce themselves to the Life Sciences community.

*Limited places are available and only to MT members from (R&D) life sciences companies who are attending the conference.*

08:00      **Investors forum part 1 - breakfast session -**  
hosted by   
INNOVATION

**MODERATOR: Dr. Harrold van Barlingen**, Managing Partner at **Thuja Capital**

*The investors forum is an exciting opportunity for those companies looking for equity capital and/or partnerships with companies and institutes across the life sciences value chain, from biotech, medtech and pharma companies to financiers and universities. The forum offers excellent opportunities for presenting your company or university to all major Dutch life sciences investors and discuss your business strategy, technology direction and capital-raising plan.*

Pitching companies:

- Keystonemab b.v.
- Digi.bio
- Phlox Therapeutics
- VivArt-X
- Sella Therapies

---

08:45      **Registration desk, exhibition open**

---



09:30-10:45 **Plenary morning programme**

hosted by



09:30 **Welcome by chair Ida Haisma, Director Leiden Bio Science Park**

09:35 **Opening by Carmen van Vilsteren, Chair Top Sector Life Science & Health**

09:45 **Novel manufacturing solutions for the rapid and cost-effective development of vaccines by Alfred Luitjens, Global Technical Sales Director Batavia Biosciences**

There is a constant demand for more affordable vaccines for global health (polio, measles, rubella), as well as new vaccines to protect against emerging virus outbreaks, such as Ebola, Lassa, Marburg, and coronavirus. To keep up with such demand, breakthrough technologies and global collaborations are required that allow flexible, cost-effective and rapid vaccine development. In this presentation, promising novel technologies, flexible manufacturing solutions and views on collaborations within the industry will be presented. These innovations have demonstrated to substantially lower the cost of goods and increase speed of manufacturing. Such innovations are deemed critical to stay ahead of the game and keep millions of people from dying from vaccine preventable diseases.

10:15 **Plans of BMS for the manufacturing of current and future CAR-T therapies in the EU**  
**Arjen Schippers, Senior Director and Program Head at**  
**Europe Cell Therapy Facility, Bristol Myers Squibb Leiden**

Presentation on the plans of BMS for the manufacturing of current and future CAR-T therapies in the EU. What are CAR-T therapies, what is the best way to produce them in the EU and what are some of the challenges that you can face during startup of a new site. What are the future manufacturing scenarios for BMS.

10:50 **Break**  
 Exhibition open



## 11:30-12:45 Parallel morning sessions

<p><b>Advance biopharmaceutical manufacturing</b></p> <p>Hosted by</p>  <p>Chair: André van de Sande MSc, MBA</p>	<p>A greater prevalence of large molecule drugs, an increase in the number of personalized medicines, the rise of orphan diseases and the high demand of vaccines reflects the global pharmaceutical portfolio. This need for high quality and complex medicines is driving innovation in biopharmaceutical manufacturing technologies. Trends and developments are discussed in this session.</p>	<p>Presentations by:</p> <ul style="list-style-type: none"> <li>▪ <b>Dr. Nettie Buitelaar</b>, Chief Business Officer at BiosanaPharma</li> <li>▪ <b>Mireille Sanders MSc</b>, Chief Operations Officer at Pharming Group NV</li> <li>▪ <b>Alexander Willemse</b>, CEO BioConnection</li> </ul>
<p><b>The Nagoya protocol: its impact on research and development in life sciences</b></p> <p>Hosted by</p>  <p>Chair: Frits Michiels</p>	<p>In this session the critical importance of the growing role of the Nagoya protocol on the access to genetic resources and the fair and equitable sharing of benefits arising from their utilization. What is the impact of the Nagoya protocol on your product development related to the use of pathogens and sequence data? What are the actions to be taken by the companies?</p>	<p>Presentations by:</p> <ul style="list-style-type: none"> <li>▪ <b>Dr. Martin Brink</b>, Policy Advisor Centre for Genetic Resources, the Netherlands (CGN), WUR</li> <li>▪ <b>Dr. Scarlett Sett</b>, ABS Project Officer (EVA project) at Leibniz Institute DSMZ - German Collection of Microorganisms and Cell Cultures</li> <li>▪ <b>Dr. Noël van Peij</b>, Principal Scientist DSM Food Specialties</li> </ul>
<p><b>Medical devices to respond to urgent needs</b></p> <p>Hosted by</p>  <p>Chair: Wim Steenackers</p>	<p>Medical devices are playing an important role in diagnosing, monitoring, preventing, and treating of COVID-19. Medical devices companies leverage the latest technological advancements to fulfil unmet needs of patients and health care providers. As medical devices and in-vitro medical devices are strictly regulated, implementing new technologies not only comes with technical challenges, but also with challenges in, e.g., the design and the development and the manufacturing of devices. The two presenters in this session will share their experience in this matter.</p>	<p>Presentations by:</p> <ul style="list-style-type: none"> <li>▪ <b>Koen Beyers</b>, Founder &amp; Board Member at Voxdale</li> <li>▪ <b>David Nauwelaers</b>, Director of Manufacturing MiDiagnostics</li> </ul>

## 12:45-14:00 Lunch, networking > exhibition open



13:00

## Investors forum part 2 - lunch session –


hosted by **Johnson & Johnson**

INNOVATION

Pitching companies:

- GOAL 3
- AND BioPharma BV
- SLAM Ortho
- Panorama Laboratories
- Singularity Bio

## 14:00-15:15 Parallel afternoon sessions

<p><b>Cell- and gene based therapeutics</b></p> <p>Hosted by</p>  <p>Chair: Dr. Frank van Engelenburg</p>	<p>Which next generation cell- and gene based therapeutics are being developed and tested in the clinic. What are the market developments and how will the industry meet the high demand of cell- and gene therapy products?</p>	<p>Presentations by:</p> <ul style="list-style-type: none"> <li>▪ <b>Dr.Ir. Hugo Cueto Rojas</b>, USP Lead Scientist uniQure</li> <li>▪ <b>Dr. Melissa van Pel</b>, Head of Cell Therapy at NecstGen</li> <li>▪ <b>Erik Agterhuis</b>, Industry Supply Chain expert and former Director Supply Chain Cell Therapy at Kite Pharma</li> </ul>
<p><b>Human Microbiome: novel therapeutic strategies and market developments</b></p> <p>Hosted by</p>  <p>Chair: Erik Boonen</p>	<p>Understanding mechanism of action and translating microbiome science into commercially viable therapeutics remains the biggest challenge in this emerging field. Pharma and biotech across many different therapeutic indications and modalities are bringing novel microbiome-based therapies and diagnostics to the clinical domain. This session will include some of the most impactful and promising areas of the microbiome field.</p>	<p>Presentations by:</p> <ul style="list-style-type: none"> <li>▪ <b>Dr. Dries Budding</b>, CEO inBiome</li> <li>▪ <b>Marco van Es</b>, Founder Bac2nature</li> <li>▪ <b>Dr. Jonathan de Jonge</b>, COO ARTPred</li> </ul>
<p><b>Breakthrough technologies in life sciences</b></p> <p>Hosted by:</p>  <p>Chair: Drs. Stéfan Ellenbroek</p>	<p>What are technologies that will help the life sciences sector and generate impact for patients. Along with substantial investments in drug discovery, research and development, life sciences companies are also transforming in the new technological areas. In this session these breakthrough technologies will be discussed.</p>	<p>Presentations by:</p> <ul style="list-style-type: none"> <li>▪ <b>Jos Lunenberg MSc, MBA</b>, Founder &amp; CEO at ENPICOM BV</li> <li>▪ <b>Dr. Kirsten Schimmel</b>, Ziekenhuisapotheker   Sectiehoofd Bereidingen   Associate Professor Drug Manufacturing at LUMC</li> <li>▪ <b>Frederico Muffatto</b>, CEO Digi.Bio</li> <li>▪ <b>Jan Jaap Verhoef</b>, Founder Imuno</li> </ul>





15:15 **Break, networking > exhibition open**

---

16:00 **Wrap up conference**

---

16.10 **Announcement winner Investors Forum**

---

16:25 **Mibiton Quality Certificate**

Already more than twenty-five years, dozens of young Life Sciences companies has already been able to accelerate their development, by using a Mibiton investment to purchase state-of-the art lab facilities or to produce first series of medical devices or agro-food production facilities. This year, the stem cell company Ncardia, with facilities at the Leiden Bio Science Park, was selected to receive the bi-annual “Mibiton Quality Certificate”. CEO Stefan Braam will briefly elaborate on the recent developments of his company, including the impact of both Mibiton investments.

---

16:35 **TargED Biopharmaceuticals: from Idea to Company**

**Kristof Vercruysse**, CEO and Co-Founder **TargED Biopharmaceuticals B.V.**

Kristof will explain what are the necessary steps to go from idea towards clinical development! What are the do's and don'ts while setting up your company for the next steps. Building a story that is comprehensible and reproducible, a strategy that even holds in difficult therapeutic areas.

---

17:05 **Venture Challenge**

hosted by **Health~Holland**

*The winners of the Venture Challenge Summer and Fall 2021 will be announced!*

Presentation by **Dr.ir. Chrétien Herben**, Program Director **Life Sciences@Work**

17:30 **End of conference**

**Reception > exhibition open**

18:30 **End of the Dutch Life Sciences conference**

*Note: the organisation keeps the right to make changes to the programme at any time.*